Lyell Immunopharma, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $36.0K | $61.0K | $130.0K | $84.7M | $10.7M | $7.8M | $657.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | $182.9M | $159.2M | $138.7M | $182.2M | $63.6M |
| SG&A Expense | — | $45.1M | $52.0M | $67.0M | $117.3M | $89.1M | $46.9M | $39.2M |
| Operating Income | — | $-269.4M | $-358.8M | $-247.0M | $-187.1M | $-214.8M | $-211.9M | $-102.1M |
| Operating Margin | — | -748,344.4% | -588,123.0% | -190,006.2% | -220.9% | -2,016.7% | -2,732.6% | -15,538.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | — | — | — |
| Net Income | — | $-274.4M | $-343.0M | $-234.6M | $-183.1M | $-250.2M | $-204.5M | $-129.4M |
| Net Margin | — | -762,355.6% | -562,285.2% | -180,486.2% | -216.2% | -2,349.5% | -2,636.3% | -19,692.1% |
| EPS (Basic) | — | $-16.06 | $-26.23 | $-18.70 | $-0.74 | $-1.84 | $-1.57 | $0.00 |
| EPS (Diluted) | — | $-16.06 | $-26.23 | $-18.70 | $-0.74 | $-1.84 | $-1.57 | $0.00 |
| Shares Outstanding (Basic) | 23.3M | 17.1M | 13.1M | 12.5M | 247.1M | 135.9M | 132.6M | 132.6M |
| Shares Outstanding (Diluted) | 23.3M | 17.1M | 13.1M | 12.5M | 247.1M | 135.9M | 132.6M | 132.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |